Official source · cited records
Federal Register via GovInfo
228 public records from Federal Register via GovInfo that PeptideScanner profiles or records cite, newest check first. Inclusion is not a source rating, endorsement, or claim of comprehensive monitoring.
Page 1 of 1
Official source · 228 cited records
- Federal Register notice 2011-27327 · published 2011-10-24 · Oncologic Drugs Advisory Committee; Notice of Meeting ↗Source checked November 17, 2026
- Federal Register notice 2012-10154 · published 2012-04-27 · Oncologic Drugs Advisory Committee; Notice of Meeting ↗Source checked November 17, 2026
- Federal Register notice 2013-25588 · published 2013-10-30 · Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting ↗Source checked November 17, 2026
- Federal Register notice 2014-02942 · published 2014-02-12 · Anti-Infective Drugs Advisory Committee; Notice of Meeting ↗Source checked November 17, 2026
- Federal Register notice 2014-11175 · published 2014-05-15 · Determination of Regulatory Review Period for Purposes of Patent Extension; KYPROLIS ↗Source checked November 17, 2026
- Federal Register notice 2014-11523 · published 2014-05-20 · Determination of Regulatory Review Period for Purposes of Patent Extension; OMONTYS ↗Source checked November 17, 2026
- Federal Register notice 2016-08682 · published 2016-04-15 · Product-Specific Bioequivalence Recommendations; Draft and Revised Draft Guidances for Industry; Availability ↗Source checked November 17, 2026
- Federal Register notice 2016-13797 · published 2016-06-10 · Determination of Regulatory Review Period for Purposes of Patent Extension; TANZEUM ↗Source checked November 17, 2026
- Federal Register notice 2016-22935 · published 2016-09-23 · Determination of Regulatory Review Period for Purposes of Patent Extension; MYALEPT ↗Source checked November 17, 2026
- Federal Register notice 2018-02768 · published 2018-02-12 · Determination of Regulatory Review Period for Purposes of Patent Extension; DALVANCE ↗Source checked November 17, 2026
- Federal Register notice 2018-15735 · published 2018-07-23 · Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability ↗Source checked November 17, 2026
- Federal Register notice 2019-02146 · published 2019-02-13 · Takeda Pharmaceuticals U.S.A., Inc.; Withdrawal of Approval of a New Drug Application for OMONTYS (peginesatide) Injection ↗Source checked November 17, 2026
- Federal Register notice 2019-09007 · published 2019-05-03 · 21st Century Cures Act: Annual Compilation of Notices of Updates From the Susceptibility Test Interpretive Criteria Web Page; Request for Comments ↗Source checked November 17, 2026
- Federal Register notice 2026-15149 · published 2026-07-28 · Pediatric Advisory Committee (PAC); Notice of Meeting; Establishment of a Public Docket; Request for Comments ↗Source checked November 17, 2026
- Federal Register notice 97-10541 · published 1997-04-23 · Advisory Committee; Notice of Meeting ↗Source checked November 17, 2026
- Federal Register notice 98-7053 · published 1998-03-19 · Peripheral and Central Nervous System Drugs Advisory Committee; Notice of Meeting ↗Source checked November 17, 2026
- Federal Register notice E6-12571 · published 2006-08-03 · Determination of Regulatory Review Period for Purposes of Patent Extension; IPLEX ↗Source checked November 17, 2026
- Federal Register notice E6-9138 · published 2006-06-13 · Determination of Regulatory Review Period for Purposes of Patent Extension; INCRELEX ↗Source checked November 17, 2026
- Federal Register proposed rule 2015-32246 · published 2015-12-23 · Fixed-Combination and Co-Packaged Drugs: Applications for Approval and Combinations of Active Ingredients Under Consideration for Inclusion in an Over-the-Counter Monograph ↗Source checked November 17, 2026
- Federal Register notice 01-10450 · published 2001-04-27 · Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting ↗Source checked November 16, 2026
- Federal Register notice 01-11071 · published 2001-05-03 · Elanco Animal Health, A Div. of Eli Lilly & Co. et al.; Withdrawal of Approval of NADAs ↗Source checked November 16, 2026
- Federal Register notice 01-11620 · published 2001-05-09 · Purina Mills, Inc., et al.; Withdrawal of Approval of New Animal Drug Applications ↗Source checked November 16, 2026
- Federal Register notice 03-20949 · published 2003-08-18 · Eli Lilly and Co. et al.; Withdrawal of Approval of 80 New Drug Applications and 75 Abbreviated New Drug Applications ↗Source checked November 16, 2026
- Federal Register notice 04-15570 · published 2004-07-09 · Notice of Approval of Abbreviated New Animal Drug Application; Oxytocin Injection ↗Source checked November 16, 2026
- Federal Register notice 2010-11038 · published 2010-05-11 · Pediatric Advisory Committee; Notice of Meeting ↗Source checked November 16, 2026
- Federal Register notice 2012-22195 · published 2012-09-10 · Withdrawal of Approval of New Animal Drug Applications; Chorionic Gonadotropin; Naloxone; Oxymorphone; Oxytocin ↗Source checked November 16, 2026
- Federal Register notice 2012-30308 · published 2012-12-17 · Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability ↗Source checked November 16, 2026
- Federal Register notice 2012-4037 · published 2012-02-22 · Final Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability ↗Source checked November 16, 2026
- Federal Register notice 2012-6971 · published 2012-03-23 · Gastrointestinal Drugs Advisory Committee; Notice of Meeting ↗Source checked November 16, 2026
- Federal Register notice 2013-04827 · published 2013-03-04 · Determination That GEREF (Sermorelin Acetate) Injection, 0.5 Milligrams Base/Vial and 1.0 Milligrams Base/Vial, and GEREF (Sermorelin Acetate) Injection, 0.05 Milligrams Base/Amp, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness ↗Source checked November 16, 2026
- Federal Register notice 2014-28702 · published 2014-12-09 · Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting ↗Source checked November 16, 2026
- Federal Register notice 2015-09299 · published 2015-04-22 · Determination That OXYTOCIN in 5% Dextrose Injection Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness ↗Source checked November 16, 2026
- Federal Register notice 2016-14418 · published 2016-06-20 · Bone, Reproductive and Urologic Drugs Advisory Committee; Notice of Meeting ↗Source checked November 16, 2026
- Federal Register notice 2017-16581 · published 2017-08-07 · Product-Specific Guidances; Final Guidances for Industry; Availability ↗Source checked November 16, 2026
- Federal Register notice 2019-10165 · published 2019-05-16 · Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability ↗Source checked November 16, 2026
- Federal Register notice 2020-10367 · published 2020-05-14 · Janssen Pharmaceuticals, Inc., et al.; Withdrawal of Approval of 16 New Drug Applications ↗Source checked November 16, 2026
- Federal Register notice 2021-00118 · published 2021-01-08 · Determination That ARALEN (Chloroquine Phosphate) Oral Tablets, 500 Milligrams, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness ↗Source checked November 16, 2026
- Federal Register notice 2022-25549 · published 2022-11-23 · List of Bulk Drug Substances for Which There is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act ↗Source checked November 16, 2026
- Federal Register notice 2023-02442 · published 2023-02-06 · Determination That TRIAMCINOLONE ACETONIDE (Triamcinolone Acetonide) Topical Cream, 0.025% and 0.1%, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness ↗Source checked November 16, 2026
- Federal Register notice 2023-26255 · published 2023-11-29 · Determination of Regulatory Review Period for Purposes of Patent Extension; Empaveli ↗Source checked November 16, 2026
- Federal Register notice 2023-26260 · published 2023-11-30 · Determination of Regulatory Review Period for Purposes of Patent Extension; ZEGALOGUE ↗Source checked November 16, 2026
- Federal Register notice 2024-25391 · published 2024-10-31 · Product-Specific Guidances; Revised Draft Guidances for Industry; Availability ↗Source checked November 16, 2026
- Federal Register notice 2024-26913 · published 2024-11-19 · Pfizer, Inc., et al.; Withdrawal of Approval of 26 New Drug Applications ↗Source checked November 16, 2026
- Federal Register notice 97-19065 · published 1997-07-21 · Babineaux's Veterinary Products, Inc., et al.; Withdrawal of Approval of NADA's ↗Source checked November 16, 2026
- Federal Register notice 97-20871 · published 1997-08-07 · Sterling Drug, Inc., et al.; Withdrawal of Approval of 28 New Drug Applications, 9 Abbreviated Antibiotic Applications, and 46 Abbreviated New Drug Applications ↗Source checked November 16, 2026
- Federal Register notice 97-30614 · published 1997-11-21 · Determination That Desmopressin Acetate Nasal Solution 0.01% (for Refrigerated Storage) Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness ↗Source checked November 16, 2026
- Federal Register notice 98-33915 · published 1998-12-23 · Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting ↗Source checked November 16, 2026
- Federal Register notice E6-15554 · published 2006-09-20 · Determination of Regulatory Review Period for Purposes of Patent Extension; FUZEON ↗Source checked November 16, 2026
- Federal Register notice E6-16091 · published 2006-10-02 · Determination of Regulatory Review Period for Purposes of Patent Extension; NATRECOR ↗Source checked November 16, 2026
- Federal Register notice E9-11628 · published 2009-05-19 · Novartis Pharmaceuticals Corp. et al.; Withdrawal of Approval of 92 New Drug Applications and 49 Abbreviated New Drug Applications ↗Source checked November 16, 2026
- Federal Register notice E9-28593 · published 2009-12-01 · Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability ↗Source checked November 16, 2026
- Federal Register rule 00-18828 · published 2000-07-26 · New Animal Drugs; Change of Sponsor ↗Source checked November 16, 2026
- Federal Register rule 01-11070 · published 2001-05-03 · Animal Drugs, Feeds, and Related Products; Tylosin Tartrate for Injection, etc.; Withdrawal of Approval of NADAs ↗Source checked November 16, 2026
- Federal Register rule 01-11621 · published 2001-05-09 · Animal Drugs, Feeds, and Related Products; Trichlorfon, etc.; Withdrawal of Approval of NADAs ↗Source checked November 16, 2026
- Federal Register rule 03-15618 · published 2003-06-20 · Dosage Form New Animal Drugs; Change of Sponsor; Technical Amendment ↗Source checked November 16, 2026
- Federal Register rule 2012-22196 · published 2012-09-10 · New Animal Drugs; Chorionic Gonadotropin; Naloxone; Oxymorphone; Oxytocin ↗Source checked November 16, 2026
- Federal Register rule 2013-06126 · published 2013-03-22 · New Animal Drugs; Changes of Sponsor ↗Source checked November 16, 2026
- Federal Register rule 2013-07542 · published 2013-04-09 · New Animal Drugs; Change of Sponsor ↗Source checked November 16, 2026
- Federal Register rule 2014-06131 · published 2014-03-25 · Implantation or Injectable Dosage Form New Animal Drugs; Change of Sponsor ↗Source checked November 16, 2026
- Federal Register rule 2016-13517 · published 2016-06-08 · New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Applications; Changes of Sponsorship ↗Source checked November 16, 2026
- Federal Register rule 2018-06358 · published 2018-03-30 · New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Applications; Changes of Sponsorship; Change of a Sponsor's Name and Address ↗Source checked November 16, 2026
- Federal Register rule 2019-04226 · published 2019-03-13 · New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Applications; Changes of Sponsorship ↗Source checked November 16, 2026
- Federal Register rule 95-15241 · published 1995-06-22 · New Animal Drugs; Change of Sponsor ↗Source checked November 16, 2026
- Federal Register rule 97-16967 · published 1997-06-30 · Animal Drugs, Feeds, and Related Products; Change of Sponsor ↗Source checked November 16, 2026
- Federal Register rule 97-19066 · published 1997-07-21 · Animal Drugs, Feeds, and Related Products ↗Source checked November 16, 2026
- Federal Register rule E8-24050 · published 2008-10-09 · Distribution of Certain Drug Products by Registered Blood Establishments and Comprehensive Hemophilia Diagnostic Treatment Centers That Qualify as Health Care Entities; Prescription Drug Marketing Act of 1987; Prescription Drug Amendments of 1992; Policies, Requirements and Administrative Procedures ↗Source checked November 16, 2026
- Federal Register notice 04-24378 · published 2004-11-02 · Determination of Regulatory Review Period for Purposes of Patent Extension; GANIRELIX ACETATE INJECTION (Formerly ANTAGON) ↗Source checked November 15, 2026
- Federal Register notice 2010-31583 · published 2010-12-16 · Determination of Regulatory Review Period for Purposes of Patent Extension; ANGIOMAX ↗Source checked November 15, 2026
- Federal Register notice 2010-4159 · published 2010-03-01 · Determination of Regulatory Review Period for Purposes of Patent Extension; FIRMAGON ↗Source checked November 15, 2026
- Federal Register notice 2011-12543 · published 2011-05-23 · Pulmonary-Allergy Drugs Advisory Committee; Notice of Meeting ↗Source checked November 15, 2026
- Federal Register notice 2012-12040 · published 2012-05-18 · Determination That PITRESSIN TANNATE IN OIL (Vasopressin Tannate) Injection, 5 Pressor Units/Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness ↗Source checked November 15, 2026
- Federal Register notice 2012-20612 · published 2012-08-22 · Gastrointestinal Drugs Advisory Committee; Notice of Meeting ↗Source checked November 15, 2026
- Federal Register notice 2012-22658 · published 2012-09-14 · Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability ↗Source checked November 15, 2026
- Federal Register notice 2012-25483 · published 2012-10-17 · Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting ↗Source checked November 15, 2026
- Federal Register notice 2013-00507 · published 2013-01-14 · Joint Meeting of the Advisory Committee for Reproductive Health Drugs and the Drug Safety and Risk Management Advisory Committee; Notice of Meeting ↗Source checked November 15, 2026
- Federal Register notice 2014-07331 · published 2014-04-02 · Determination of Regulatory Review Period for Purposes of Patent Extension; FIRAZYR ↗Source checked November 15, 2026
- Federal Register notice 2015-10994 · published 2015-05-07 · Determination of Regulatory Review Period for Purposes of Patent Extension; SIGNIFOR ↗Source checked November 15, 2026
- Federal Register notice 2015-11000 · published 2015-05-07 · Determination of Regulatory Review Period for Purposes of Patent Extension; GATTEX ↗Source checked November 15, 2026
- Federal Register notice 2015-11003 · published 2015-05-07 · Determination of Regulatory Review Period for Purposes of Patent Extension; OVUGEL ↗Source checked November 15, 2026
- Federal Register notice 2016-27244 · published 2016-11-14 · Edward Manookian (Also Known as Ed Manning): Debarment Order ↗Source checked November 15, 2026
- Federal Register notice 2018-18614 · published 2018-08-28 · List of Bulk Drug Substances for Which There is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act ↗Source checked November 15, 2026
- Federal Register notice 2018-25187 · published 2018-11-19 · Determination That REGITINE (Phentolamine Mesylate) Injection, 5 Milligrams/Vial, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness ↗Source checked November 15, 2026
- Federal Register notice 2018-28221 · published 2018-12-28 · Determination of Regulatory Review Period for Purposes of Patent Extension; PARSABIV ↗Source checked November 15, 2026
- Federal Register notice 2019-03129 · published 2019-02-25 · Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability ↗Source checked November 15, 2026
- Federal Register notice 2019-03810 · published 2019-03-04 · List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act ↗Source checked November 15, 2026
- Federal Register notice 2019-06385 · published 2019-04-02 · Post-Marketing Pediatric-Focused Product Safety Reviews; Establishment of a Public Docket; Request for Comments ↗Source checked November 15, 2026
- Federal Register notice 2019-18932 · published 2019-09-03 · List of Bulk Drug Substances for Which There is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act ↗Source checked November 15, 2026
- Federal Register notice 2019-19347 · published 2019-09-09 · Determination That CALCIMAR (calcitonin salmon) Injection, 200 International Units Per Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness ↗Source checked November 15, 2026
- Federal Register notice 2020-14719 · published 2020-07-08 · Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments ↗Source checked November 15, 2026
- Federal Register notice 2020-16649 · published 2020-07-31 · List of Bulk Drug Substances for Which There is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act ↗Source checked November 15, 2026
- Federal Register notice 2020-23300 · published 2020-10-21 · Determination That BUTISOL SODIUM (Butabarbital Sodium) Oral Tablets, 15 Milligrams, 50 Milligrams, and 100 Milligrams, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness ↗Source checked November 15, 2026
- Federal Register notice 2020-23439 · published 2020-10-22 · 21st Century Cures Act: Annual Compilation of Notices of Updates From the Susceptibility Test Interpretive Criteria Web Page; Request for Comments ↗Source checked November 15, 2026
- Federal Register notice 2020-26133 · published 2020-11-25 · Termination of the Food and Drug Administration's Unapproved Drugs Initiative; Request for Information Regarding Drugs Potentially Generally Recognized as Safe and Effective ↗Source checked November 15, 2026
- Federal Register notice 2021-16047 · published 2021-07-28 · Fresenius Kabi USA, LLC, et al.; Withdrawal of Approval of 15 Abbreviated New Drug Applications ↗Source checked November 15, 2026
- Federal Register notice 2021-25111 · published 2021-11-18 · Discovery Therapeutics, LLC, et al.; Withdrawal of Approval of 18 Abbreviated New Drug Applications ↗Source checked November 15, 2026
- Federal Register notice 2022-01693 · published 2022-01-28 · 21st Century Cures Act: Annual Compilation of Notices of Updates From the Susceptibility Test Interpretive Criteria Web Page; Request for Comments ↗Source checked November 15, 2026
- Federal Register notice 2022-17056 · published 2022-08-09 · Determination That AVC (Sulfanilamide) Vaginal Cream, 15%, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness ↗Source checked November 15, 2026
- Federal Register notice 2022-25210 · published 2022-11-18 · Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability ↗Source checked November 15, 2026
- Federal Register notice 2023-03389 · published 2023-02-17 · Determination That MIACALCIN (Calcitonin Salmon) Injection, 100 USP Units/Milliliter (mL), Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness ↗Source checked November 15, 2026
- Federal Register notice 2023-04175 · published 2023-03-01 · Mylan Pharmaceuticals Inc., et.al.; Withdrawal of Approval of 11 Abbreviated New Drug Applications ↗Source checked November 15, 2026
- Federal Register notice 2023-06593 · published 2023-03-30 · Issuance of Priority Review Voucher; Rare Pediatric Disease Product ↗Source checked November 15, 2026
- Federal Register notice 2023-10710 · published 2023-05-19 · Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability ↗Source checked November 15, 2026
- Federal Register notice 2023-16775 · published 2023-08-07 · Determination That CUBICIN (Daptomycin) Powder for Injection, 250 Milligrams/Vial and 500 Milligrams/Vial, and CUBICIN RF (Daptomycin) Powder for Injection, 500 Milligrams/Vial, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness ↗Source checked November 15, 2026
- Federal Register notice 2023-19013 · published 2023-09-05 · Merck Sharp & Dohme LLC, et al.; Withdrawal of Approval of 35 New Drug Applications ↗Source checked November 15, 2026
- Federal Register notice 2023-24120 · published 2023-11-01 · Determination That CALCIUM DISODIUM VERSENATE (Edetate Calcium Disodium) Injection, 200 Milligrams per Milliliter, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness ↗Source checked November 15, 2026
- Federal Register notice 2023-26106 · published 2023-11-28 · Determination of Regulatory Review Period for Purposes of Patent Extension; Korsuva ↗Source checked November 15, 2026
- Federal Register notice 2024-03300 · published 2024-02-16 · Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability ↗Source checked November 15, 2026
- Federal Register notice 2024-16618 · published 2024-07-29 · Pediatric Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments ↗Source checked November 15, 2026
- Federal Register notice 2024-21941 · published 2024-09-25 · Determination of Regulatory Review Period for Purposes of Patent Extension; DAYBUE ↗Source checked November 15, 2026
- Federal Register notice 2025-06048 · published 2025-04-09 · 21st Century Cures Act: Annual Compilation of Notices of Updates From the Susceptibility Test Interpretive Criteria Web Page; Request for Comments ↗Source checked November 15, 2026
- Federal Register notice 2025-09068 · published 2025-05-21 · Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability ↗Source checked November 15, 2026
- Federal Register notice 2025-11314 · published 2025-06-20 · Determination of Regulatory Review Period for Purposes of Patent Extension; ZILBRYSQ ↗Source checked November 15, 2026
- Federal Register notice 2025-16269 · published 2025-08-26 · Determination of Regulatory Review Period for Purposes of Patent Extension; YORVIPATH ↗Source checked November 15, 2026
- Federal Register notice 2025-18453 · published 2025-09-24 · Elite Laboratories, Inc., et al.; Withdrawal of Approval of 72 Abbreviated New Drug Applications ↗Source checked November 15, 2026
- Federal Register notice 2026-10277 · published 2026-05-22 · Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability ↗Source checked November 15, 2026
- Federal Register notice 2026-11062 · published 2026-06-03 · Elite Laboratories, Inc. et al.; Withdrawal of Approval of 16 Abbreviated New Drug Applications ↗Source checked November 15, 2026
- Federal Register notice 2026-13492 · published 2026-07-06 · Determination That VASOPRESSIN IN SODIUM CHLORIDE (vasopressin) 0.9%, Injection, 50 units/50 milliliters (1 unit/milliliters) Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness ↗Source checked November 15, 2026
- Federal Register notice 97-10911 · published 1997-04-28 · Environmental Assessments and Findings of No Significant Impact ↗Source checked November 15, 2026
- Federal Register notice 97-32874 · published 1997-12-17 · Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting ↗Source checked November 15, 2026
- Federal Register notice 98-25360 · published 1998-09-23 · Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting ↗Source checked November 15, 2026
- Federal Register notice 98-25713 · published 1998-09-25 · Parke-Davis Pharmaceutical Research et al.; Withdrawal of Approval of 14 New Drug Applications and 13 Abbreviated New Drug Applications ↗Source checked November 15, 2026
- Federal Register notice E6-1069 · published 2006-01-30 · Anti-Infective Drugs Advisory Committee; Notice of Meeting ↗Source checked November 15, 2026
- Federal Register notice E6-9031 · published 2006-06-09 · Determination of Regulatory Review Period for Purposes of Patent Extension; CETROTIDE ↗Source checked November 15, 2026
- Federal Register notice E6-9225 · published 2006-06-14 · Determination of Regulatory Review Period for Purposes of Patent Extension; CUBICIN ↗Source checked November 15, 2026
- Federal Register notice E7-21886 · published 2007-11-07 · Lederle Laboratories et al.; Withdrawal of Approval of 73 New Drug Applications and 62 Abbreviated New Drug Applications ↗Source checked November 15, 2026
- Federal Register notice E7-24812 · published 2007-12-21 · Pulmonary-Allergy Drugs Advisory Committee; Notice of Meeting ↗Source checked November 15, 2026
- Federal Register rule 2012-25989 · published 2012-10-23 · New Animal Drugs; Approvals; Changes of Sponsor; Change of Sponsor's Name; Change of Sponsor's Address; Alfaxalone; Ivermectin and Clorsulon; Narasin; Triptorelin ↗Source checked November 15, 2026
- Federal Register rule 2025-01226 · published 2025-01-21 · New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Applications; Change of Sponsor; Change of Sponsor Address ↗Source checked November 15, 2026
- Federal Register notice 2026-17222 · published 2026-08-24 · Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability ↗Source checked November 14, 2026
- Federal Register notice 2026-23141 · published 2026-11-13 · Determination That DIBENZYLINE (Phenoxybenzamine Hydrochloride) Oral Capsule, 10 Milligrams, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness ↗Source checked November 14, 2026
- Federal Register notice 00-1872 · published 2000-01-27 · Determination of Regulatory Review Period for Purposes of Patent Extension; GlucaGen® ↗Source checked August 21, 2026
- Federal Register notice 01-14410 · published 2001-06-08 · Endocrinologic and Metabolic Drugs Advisory Committe; Notice of Meeting ↗Source checked August 21, 2026
- Federal Register notice 05-20301 · published 2005-10-07 · Solicitation of Public Review and Comment on Research Protocol: Gonadotropin-releasing Hormone Agonist Test in Disorders of Puberty ↗Source checked August 21, 2026
- Federal Register notice 05-20302 · published 2005-10-07 · Pediatric Ethics Subcommittee of the Pediatric Advisory Committee; Notice of Meeting ↗Source checked August 21, 2026
- Federal Register notice 2010-6169 · published 2010-03-22 · Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting ↗Source checked August 21, 2026
- Federal Register notice 2010-785 · published 2010-01-19 · Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting ↗Source checked August 21, 2026
- Federal Register notice 2011-14164 · published 2011-06-08 · Bristol-Myers Squibb Co. et al.; Withdrawal of Approval of 70 New Drug Applications and 97 Abbreviated New Drug Applications ↗Source checked August 21, 2026
- Federal Register notice 2012-10517 · published 2012-05-02 · Determination of Regulatory Review Period for Purposes of Patent Extension; Victoza ↗Source checked August 21, 2026
- Federal Register notice 2012-10808 · published 2012-05-04 · Determination of Regulatory Review Period for Purposes of Patent Extension; EGRIFTA ↗Source checked August 21, 2026
- Federal Register notice 2012-1433 · published 2012-01-25 · Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability ↗Source checked August 21, 2026
- Federal Register notice 2014-07330 · published 2014-04-02 · Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability ↗Source checked August 21, 2026
- Federal Register notice 2014-11926 · published 2014-05-23 · Determination of Regulatory Review Period for Purposes of Patent Extension; LINZESS ↗Source checked August 21, 2026
- Federal Register notice 2014-17293 · published 2014-07-23 · Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability ↗Source checked August 21, 2026
- Federal Register notice 2014-18304 · published 2014-08-04 · Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting ↗Source checked August 21, 2026
- Federal Register notice 2014-19713 · published 2014-08-20 · Determination That LUPRON DEPOT-PED (Leuprolide Acetate for Depot Suspension), Injectable 3.75 Milligrams/Vial and 7.5 Milligrams/Vial; and LUPRON DEPOT-PED (Leuprolide Acetate for Depot Suspension), Injectable 7.5 Milligrams/Vial and 7.5 Milligrams/Vial, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness ↗Source checked August 21, 2026
- Federal Register notice 2014-23961 · published 2014-10-08 · Determination That LUPRON DEPOT (Leuprolide Acetate for Depot Suspension), Injectable 3.75 Milligrams/Vial Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness ↗Source checked August 21, 2026
- Federal Register notice 2015-22673 · published 2015-09-09 · Determination That GLUCAGON (Glucagon Hydrochloride) for Injection, Equivalent to 1 Milligram Base/Vial and Equivalent to 10 Milligram Base/Vial, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness ↗Source checked August 21, 2026
- Federal Register notice 2016-05931 · published 2016-03-16 · Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting ↗Source checked August 21, 2026
- Federal Register notice 2016-05959 · published 2016-03-17 · Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting ↗Source checked August 21, 2026
- Federal Register notice 2016-30399 · published 2016-12-19 · Determination of Regulatory Review Period for Purposes of Patent Extension; TRULICITY ↗Source checked August 21, 2026
- Federal Register notice 2017-10326 · published 2017-05-22 · Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments ↗Source checked August 21, 2026
- Federal Register notice 2017-12908 · published 2017-06-21 · Wyeth Pharmaceuticals Inc. et al.; Withdrawal of Approval of 121 New Drug Applications and 161 Abbreviated New Drug Applications ↗Source checked August 21, 2026
- Federal Register notice 2017-21176 · published 2017-10-03 · Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments ↗Source checked August 21, 2026
- Federal Register notice 2017-21202 · published 2017-10-03 · Abbreviated New Drug Applications for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of Recombinant Deoxyribonucleic Acid Origin; Draft Guidance for Industry; Availability ↗Source checked August 21, 2026
- Federal Register notice 2017-25920 · published 2017-12-01 · Barr Laboratories, Inc. et al.; Withdrawal of Approval of 68 Abbreviated New Drug Applications ↗Source checked August 21, 2026
- Federal Register notice 2018-02667 · published 2018-02-09 · Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability ↗Source checked August 21, 2026
- Federal Register notice 2018-07256 · published 2018-04-10 · Notice of Approval of Products Under Voucher: Rare Pediatric Disease Priority Review Vouchers ↗Source checked August 21, 2026
- Federal Register notice 2018-22956 · published 2018-10-22 · Determination of Regulatory Review Period for Purposes of Patent Extension; TYMLOS ↗Source checked August 21, 2026
- Federal Register notice 2018-25950 · published 2018-11-29 · Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability ↗Source checked August 21, 2026
- Federal Register notice 2018-26289 · published 2018-12-04 · Determination of Regulatory Review Period for Purposes of Patent Extension; TRULANCE ↗Source checked August 21, 2026
- Federal Register notice 2018-27805 · published 2018-12-26 · Determination of Regulatory Review Period for Purposes of Patent Extension; ADLYXIN ↗Source checked August 21, 2026
- Federal Register notice 2018-28213 · published 2018-12-28 · Product-Specific Guidance for Linaclotide; Draft Guidance for Industry; Availability ↗Source checked August 21, 2026
- Federal Register notice 2019-11243 · published 2019-05-30 · Determination That LUPRON (Leuprolide Acetate) Injection, 1 Milligram/0.2 Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness ↗Source checked August 21, 2026
- Federal Register notice 2019-20108 · published 2019-09-17 · Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability ↗Source checked August 21, 2026
- Federal Register notice 2019-25850 · published 2019-11-29 · Determination of Regulatory Review Period for Purposes of Patent Extension; OZEMPIC ↗Source checked August 21, 2026
- Federal Register notice 2020-04320 · published 2020-03-03 · Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability ↗Source checked August 21, 2026
- Federal Register notice 2020-18240 · published 2020-08-20 · Determination of Regulatory Review Period for Purposes of Patent Extension; VYLEESI ↗Source checked August 21, 2026
- Federal Register notice 2020-27760 · published 2020-12-17 · Issuance of Priority Review Voucher; Rare Pediatric Disease Product ↗Source checked August 21, 2026
- Federal Register notice 2021-06202 · published 2021-03-25 · Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability ↗Source checked August 21, 2026
- Federal Register notice 2021-11575 · published 2021-06-02 · Determination That SANDOSTATIN (Octreotide Acetate) Injection, Equal to 0.2 Milligrams Base/Milliliter and Equal to 1 Milligrams Base/Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness ↗Source checked August 21, 2026
- Federal Register notice 2021-18072 · published 2021-08-23 · Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability ↗Source checked August 21, 2026
- Federal Register notice 2021-18928 · published 2021-09-02 · Proposal To Refuse To Approve a New Drug Application for ITCA 650 (Exenatide in DUROS Device); Opportunity for a Hearing ↗Source checked August 21, 2026
- Federal Register notice 2021-24074 · published 2021-11-04 · Determination of Regulatory Review Period for Purposes of Patent Extension; SCENESSE ↗Source checked August 21, 2026
- Federal Register notice 2021-24431 · published 2021-11-09 · Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability ↗Source checked August 21, 2026
- Federal Register notice 2022-03248 · published 2022-02-18 · Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability ↗Source checked August 21, 2026
- Federal Register notice 2022-10701 · published 2022-05-20 · Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability ↗Source checked August 21, 2026
- Federal Register notice 2022-14134 · published 2022-07-01 · Determination of Regulatory Review Period for Purposes of Patent Extension; IMCIVREE ↗Source checked August 21, 2026
- Federal Register notice 2022-16502 · published 2022-08-03 · Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability ↗Source checked August 21, 2026
- Federal Register notice 2022-18523 · published 2022-08-29 · Notice of Approval of Product Under Voucher: Material Threat Medical Countermeasure Priority Review Voucher ↗Source checked August 21, 2026
- Federal Register notice 2022-19155 · published 2022-09-06 · Issuance of Priority Review Voucher; Rare Pediatric Disease Product ↗Source checked August 21, 2026
- Federal Register notice 2023-03364 · published 2023-02-17 · Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability ↗Source checked August 21, 2026
- Federal Register notice 2023-18026 · published 2023-08-22 · Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability ↗Source checked August 21, 2026
- Federal Register notice 2023-18241 · published 2023-08-24 · Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Alternative Form of Hearing ↗Source checked August 21, 2026
- Federal Register notice 2023-18250 · published 2023-08-24 · Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments ↗Source checked August 21, 2026
- Federal Register notice 2023-25485 · published 2023-11-17 · Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability ↗Source checked August 21, 2026
- Federal Register notice 2024-04157 · published 2024-02-29 · Determination of Regulatory Review Period for Purposes of Patent Extension; MOUNJARO ↗Source checked August 21, 2026
- Federal Register notice 2024-04218 · published 2024-02-29 · Determination of Regulatory Review Period for Purposes of Patent Extension; CAMCEVI ↗Source checked August 21, 2026
- Federal Register notice 2024-04479 · published 2024-03-04 · Determination of Regulatory Review Period for Purposes of Patent Extension; VOXZOGO ↗Source checked August 21, 2026
- Federal Register notice 2024-08657 · published 2024-04-23 · PAI Holdings, LLC DBA Pharmaceutical Associates, Inc., et al.; Withdrawal of Approval of 23 New Drug Applications ↗Source checked August 21, 2026
- Federal Register notice 2024-10896 · published 2024-05-17 · Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability ↗Source checked August 21, 2026
- Federal Register notice 2024-12065 · published 2024-06-03 · Pfizer, Inc., et al.; Withdrawal of Approval of 23 New Drug Applications ↗Source checked August 21, 2026
- Federal Register notice 2024-17649 · published 2024-08-08 · Determination That DELATESTRYL (Testosterone Enanthate) Injection, 200 Milligrams/Milliliter, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness ↗Source checked August 21, 2026
- Federal Register notice 2024-18898 · published 2024-08-23 · Final Decision on the Proposal To Refuse To Approve a New Drug Application for ITCA 650 ↗Source checked August 21, 2026
- Federal Register notice 2024-18997 · published 2024-08-23 · Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability ↗Source checked August 21, 2026
- Federal Register notice 2024-20062 · published 2024-09-06 · Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-New Drug Application 215244 for Elamipretide Hydrochloride Injection ↗Source checked August 21, 2026
- Federal Register notice 2024-21241 · published 2024-09-18 · Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List; Revisions to the Withdrawn or Removed List ↗Source checked August 21, 2026
- Federal Register notice 2024-24828 · published 2024-10-25 · Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List ↗Source checked August 21, 2026
- Federal Register notice 2024-27048 · published 2024-11-20 · Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability ↗Source checked August 21, 2026
- Federal Register notice 2025-14683 · published 2025-08-04 · Teva Branded Pharmaceutical Products R&D, Inc., et al.; Withdrawal of Approval of 39 New Drug Applications ↗Source checked August 21, 2026
- Federal Register notice 2025-19281 · published 2025-10-02 · Pediatric Advisory Committee (PAC); Notice of Meeting; Establishment of a Public Docket; Request for Comments ↗Source checked August 21, 2026
- Federal Register notice 2025-19345 · published 2025-10-02 · Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability ↗Source checked August 21, 2026
- Federal Register notice 2025-20548 · published 2025-11-21 · Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability ↗Source checked August 21, 2026
- Federal Register notice 2025-22131 · published 2025-12-05 · Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability ↗Source checked August 21, 2026
- Federal Register notice 2025-23409 · published 2025-12-19 · Issuance of Priority Review Voucher; Rare Pediatric Disease Product; FORZINITY (Elamipretide) ↗Source checked August 21, 2026
- Federal Register notice 2026-02786 · published 2026-02-12 · Jeremy Spencer Brown: Final Debarment Order ↗Source checked August 21, 2026
- Federal Register notice 2026-03963 · published 2026-02-27 · Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability ↗Source checked August 21, 2026
- Federal Register notice 2026-04546 · published 2026-03-09 · Aspen Global Inc. c/o Lachman Consultant Services, Inc., et al.; Withdrawal of Approval of 46 New Drug Applications ↗Source checked August 21, 2026
- Federal Register notice 2026-07361 · published 2026-04-16 · Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List ↗Source checked August 21, 2026
- Federal Register notice 2026-08435 · published 2026-04-30 · Determination That OZEMPIC (Semaglutide) Solution, 2 Milligrams Per 1.5 Milliliters Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness ↗Source checked August 21, 2026
- Federal Register notice 2026-08552 · published 2026-05-01 · List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act ↗Source checked August 21, 2026
- Federal Register notice 2026-12937 · published 2026-06-26 · List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Extension of Comment Period ↗Source checked August 21, 2026
- Federal Register notice 2026-15285 · published 2026-07-29 · Product-Specific Guidances; Revised Draft Guidances for Industry; Availability ↗Source checked August 21, 2026
- Federal Register notice 2026-16998 · published 2026-08-20 · Advisory Committee; Endocrinologic and Metabolic Drugs Advisory Committee; Renewal ↗Source checked August 21, 2026
- Federal Register notice 98-13045 · published 1998-05-18 · Environmental Assessments and Findings of No Significant Impact ↗Source checked August 21, 2026
- Federal Register notice 98-2498 · published 1998-02-02 · Medical Devices; Exemptions From Premarket Notification and Reserved Devices; Class I ↗Source checked August 21, 2026
- Federal Register notice 99-24595 · published 1999-09-22 · Wallace Laboratories et al.; Withdrawal of Approval of 18 New Drug Applications and 44 Abbreviated New Drug Applications ↗Source checked August 21, 2026
- Federal Register notice E6-16086 · published 2006-10-02 · Determination of Regulatory Review Period for Purposes of Patent Extension; BYETTA ↗Source checked August 21, 2026
- Federal Register notice E6-17284 · published 2006-10-18 · Summaries of Medical and Clinical Pharmacology Reviews of Pediatric Studies; Availability ↗Source checked August 21, 2026
- Federal Register notice E6-3712 · published 2006-03-15 · Determination of Regulatory Review Period for Purposes of Patent Extension; PRIALT ↗Source checked August 21, 2026
- Federal Register notice E6-9414 · published 2006-06-16 · Determination of Regulatory Review Period for Purposes of Patent Extension; SYMLIN ↗Source checked August 21, 2026
- Federal Register notice E6-9440 · published 2006-06-16 · Merck & Co., Inc., et al.; Withdrawal of Approval of 65 New Drug Applications and 52 Abbreviated New Drug Applications ↗Source checked August 21, 2026
- Federal Register notice E7-4877 · published 2007-03-19 · Pediatric Advisory Committee; Notice of Meeting ↗Source checked August 21, 2026
- Federal Register notice E8-24356 · published 2008-10-15 · Pediatric Advisory Committee; Notice of Meeting ↗Source checked August 21, 2026
- Federal Register notice E8-27179 · published 2008-11-17 · Determination of Regulatory Review Period for Purposes of Patent Extension; SOMATULINE DEPOT ↗Source checked August 21, 2026
- Federal Register notice E9-13272 · published 2009-06-08 · Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability ↗Source checked August 21, 2026
- Federal Register notice E9-5024 · published 2009-03-10 · Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting ↗Source checked August 21, 2026
- Federal Register proposed rule 98-29855 · published 1998-11-12 · Medical Devices; Exemption From Premarket Notification and Reserved Devices; Class I ↗Source checked August 21, 2026
- Federal Register rule 2026-07863 · published 2026-04-22 · Medical Devices; Clinical Chemistry and Clinical Toxicology Devices; Classification of the Setmelanotide Eligibility Gene Variant Detection System ↗Source checked August 21, 2026